Skip to main content

Long-term renal outcome in methylmalonic acidemia in adolescents and adults



Chronic kidney disease (CKD) is one of the main long-term prognosis factors in methylmalonic acidemia (MMA), a rare disease of propionate catabolism. Our objective was to precisely address the clinical and biological characteristics of long-term CKD in MMA adolescent and adult patients.

Patients and methods

In this retrospective study, we included MMA patients older than 13 years who had not received kidney and/or liver transplantation. We explored tubular functions, with special attention to proximal tubular function. We measured glomerular filtration rate (mGFR) by iohexol clearance and compared it to estimated glomerular filtration rate (eGFR) by Schwartz formula and CKD-EPI.


Thirteen patients were included (M/F = 5/8). Median age was 24 years (13 to 32). Median mGFR was 57 mL/min/1.73 m2 (23.3 to 105 mL/min/1.73 m2). Ten out of 13 patients had mGFR below 90 mL/min/1.73 m2. No patient had significant glomerular proteinuria. No patient had complete Fanconi syndrome. Only one patient had biological signs suggestive of incomplete proximal tubulopathy. Four out of 13 patients had isolated potassium loss, related to a non-reabsorbable anion effect of urinary methylmalonate. Both Schwartz formula and CKD-EPI significantly overestimated GFR. Bias were respectively 16 ± 15 mL/min/1.73 m2 and 37 ± 22 mL/min/1.73 m2.


CKD is a common complication of the MMA. Usual equations overestimate GFR. Therefore, mGFR should be performed to inform therapeutic decisions such as dialysis and/or transplantation. Mild evidence of proximal tubular dysfunction was found in only one patient, suggesting that other mechanisms are involved.


Methylmalonic acidemia (MMA) is a rare and severe inborn disease of propionate catabolism [1], caused by a defect in the mitochondrial methylmalonyl-CoA mutase (MCM). MCM isomerises L-methylmalonyl-CoA into succinyl-CoA which enters the Krebs cycle (Additional file 1: Fig. S1). MCM deficiencies are due to mutations in the MUT gene, encoding MCM, or to mutations in MMAA (CblA), MMAB (CblB) and occasionally MMADHC (CblD) genes, involved in the metabolism of its cofactor adenosylcobalamin [2]. According to residual MCM activity, MUT mutations are called mut0 for indetectable residual activity or mut for low to moderate residual activity responsive to high concentrations of adenosylcobalamin [3]. MMA usually presents as acute metabolic distress at birth, when MCM deficiency is complete, or in childhood [4]. Despite several therapeutic improvements in the past 20 years, the overall outcome of patients with MMA remains unsatisfactory [1, 4,5,6]. Long-term prognosis is worsened by chronic organ damage: neurological impairment and intellectual deficiency [5, 7,8,9,10], chronic kidney disease (CKD) [4, 5, 9, 11,12,13,14,15,16], optic neuropathy [17, 18], chronic pancreatitis [7, 9, 19] and osteopenia [4].

CKD is a common complication of MMA [4, 5, 9, 11,12,13,14,15,16]. CKD manifests in childhood in half of the patients: 47% in a French cohort (n = 30, median age at onset of CKD 6.5 years, range 1.5–18.6 years) [5], 43% in a multicenter European cohort (n = 83, 7 to 33 years) [9], and 50% in an American cohort (n = 50, median age at onset 11.9 years, 2.3 to 36.3 years) [14]. CKD was defined by an estimated glomerular filtration rate (GFR) below 80 mL/min/1.73 m2 in the French cohort [5], below 60 mL/min/1.73 m2 in the European and American cohorts [9, 14]. In all these studies, mut0 patients exhibited a higher frequency and a younger age at onset of CKD. Twelve to fourteen percent of patients evolve to end-stage renal disease (ESRD) requiring renal replacement therapy. In the French cohort, hemodialysis was started in 3 patients at the age of 5.9, 8.2 and 16 years [5]. The mechanisms responsible for renal failure in MMA remain poorly understood [9, 20,21,22]. Recently, an experimental study demonstrated a link between MMA, diseased mitochondria, mitophagy dysfunction and epithelial stress in tubular renal cells [23]. However, few observations report proximal tubulopathy or distal tubular acidosis type 2 [24, 25].

Our main objective in the present study was to precisely address the clinical and biological characteristics of long-term CKD in MMA adolescent and adult patients. To this aim, we investigated tubular functions, focusing on proximal tubular function. We also assessed the long-term renal function and we compared measured GFR (mGFR) by iohexol clearance to estimated GFR (eGFR) by Schwartz formula and CKD-EPI.

Patients and methods


Twenty MMA patients older than 13 years of age were followed at Necker-Enfants Malades hospital, a French and European reference center for inborn metabolism diseases (MetabERN), between 2017 and 2018. Seven patients (6 mut0, 1 mut) had received kidney and/or liver transplantation before renal function studies and were excluded from the present study. We retrospectively included all 13 remaining MMA patients (Fig. 1). Renal function was measured in these patients during routine follow-up. This study was performed in accordance with the ethical standards of the Helsinki Declaration. All patients and/or their legal tutors provided authorization for the use of their information for research purposes.

Fig. 1

Flow chart

Blood and urine biochemical tests

Biochemical tests were performed on blood and urine samples concurrently with the renal function studies. Methylmalonic acid levels were determined by isotope dilution gas chromatography – mass spectrometry. Creatinine was measured using IDMS-traceable enzymatic measurement.

Measure of GFR by iohexol clearance (mGFR)

A direct intravenous injection of 300 mg of iohexol (OMNIPAQUE) was performed. Thereafter, plasma was harvested every hour for 5 h for determination of iohexol concentration by HPLC. Patients were asked to drink 400 mL of water for 30 min after injection of iohexol, then 150 mL per hour from the second hour to the end of the test. Iohexol clearance was used to define CKD stage according to Kidney Disease Outcomes Quality Initiative (KDIGO) CKD classification [26].

Estimated GFR (eGFR)

We used simplified Schwartz formula to calculate eGFR [27]. In the patients older than 18 years of age, we also used the CKD-EPI formula [28].

Ultrasonography measurements

Abdominal ultrasound studies were performed in all patients except one (#05) at the time of renal function studies. Renal length was measured in the longitudinal axis and compared with renal length nomograms developed for left and right kidneys separately, height being the independent variable [29].

Statistical analysis

Descriptive statistical methods (medians and ranges) were used to assess the distributions of variables. Mann–Whitney test for continuous variables and Fisher’s exact tests for categorical variables were performed. Correlations between quantitative variables were assessed with Pearson product-moment correlation coefficient. The Bland–Altman method was used for assessing agreement between mGFR and eGFR. For all analyses, a p value < 0.05 was considered as significant. All analyzes were performed using InStat 3 software (GraphPad Software, San Diego, CA) and Prism 4 (GraphPad Software).



Thirteen patients (F/M = 5/8) were included (Table 1). The median age at the time of the study was 24 years (13 to 32 years). Four patients had a neonatal onset disease (4 to 17 days) whereas 9 had a later onset disease (median age at diagnosis 6 months, 3 to 168 months). Patients were included in the following biochemical groups: mut0 (n = 3), mut (n = 4) and cblA (n = 6). Six patients had a B12-responsive disease (5 cblA and 1 mut).

Table 1 Patients’ characteristics

At the time of the study, median protein intake was 35 g/day (22 to 46 g/day). We found no association between protein intake, B12-responsive disease, MMA phenotype and age. Median plasmatic MMA was 128 µmol/L (30 to 1139 µmol/L; normal value < 0.4 µmol/L) and median urinary MMA was 914 μmol/mmol (173 to 5619 μmol/mmol; normal value < 2 µmol/mmol).

Renal morphology

Three out of 13 patients had kidney abnormalities belonging to the spectrum of Congenital Abnormalities of the Kidney and Urinary Tract (CAKUT): vesicoureteral reflux (Patient #01), left hydronephrosis on junction syndrome (#02), single pelvic kidney (#06).

Using ultrasound examination, median renal length was 101 mm (range 87 to 119 mm). Length data correspond to an average for both kidneys of each patients. The size difference of the two kidneys was less than 10 mm for all patient except one (#02), due to left hydronephrosis on junction syndrome. In the remaining 11 patients, the median size difference between the two kidneys was 5 mm (range: 1 to 9 mm). The median difference between measured and expected renal length was − 1.3 mm (range − 19 to + 12 mm; p = 0.73). Seven out of 12 MMA patients studied for kidney length had a diminished renal length compared to published nomograms [29]. Renal length was significantly lower than expected in cblA patients (median: − 9 mm, range − 19 to 1 mm, p = 0.03).

mGFR by iohexol clearance

Measured GFR by iohexol clearance was obtained in 12 out of 13 patients (a technical problem occurred for patient #06 and its result was not interpretable). Median mGFR was 56.5 mL/min/1.73 m2 (23.3 to 105.0 mL/min/1.73 m2). Only 3 out of 12 patients (2 cblA and 1 mut-) had normal renal function (Fig. 2a). Two patients had CKD stage 2, 4 had CKD stage 3a, 2 had CKD stage 3b and 1 had CKD stage 4 (Fig. 2b). Measured GFR was significantly associated with protein intake (R = 0.84 [0.45; 0.96], p = 0.002). We did not find any association between mGFR, vitamin B12-responsive disease, MMA phenotype, age, plasma and urinary AMM concentrations (Fig. 2a, c, d).

Fig. 2

Measured GFR by clearance of iohexol. a Measured GFR (mL/min/1.73 m2) according to biochemical phenotype. Medians. b Patients (n) by CKD stage according to KDIGO stages: stage 1, GFR > 90 mL/min/1.73 m2; stage 2, GFR between 60 and 90 mL/min/1.73 m2; stage 3a, GFR between 45 and 60 mL/min/1.73 m2; stage 3b, GFR between 30 and 45 mL/min/1.73 m2; stage 4, GFR between 30 and 45 mL/min/1.73 m2. c Measured GFR (mL/min/1.73 m2) according to protein intake (g/day). d Measured GFR (mL/min/1.73 m2) according to vitamin B12 responsiveness. Medians ± interquartile ranges. Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate


Median eGFR by Schwartz formula was 77 mL/min/1.73 m2 (26 to 123 mL/min/1.73 m2). Schwartz formula significantly overestimated GFR compared to mGFR: + 16 ± 15 mL/min/1.73 m2, 95% limit of agreement (LOA) [− 13 to 45 mL/min/1.73 m2] (Fig. 3a, b). Four out of 12 patients were misclassified in the KDIGO CKD classification when the Schwartz formula was used (Fig. 3c). Ten patients were over 18 years of age, allowing calculating eGFR by CKD-EPI. CKD-EPI systematically overestimated GFR compared to mGFR: + 37 ± 22 mL/min/1.73, 95% LOA [− 8 to 78 mL/min/1.73 m2] (Fig. 3a, d). Only one patient was properly classified when the CKD-EPI was used for the KDIGO CKD classification (Fig. 3e).

Fig. 3

The usual formulas for estimated GFR overestimated the renal function of MMA patients. a Measured GFR by clearance of iohexol, Estimated GFRs by Schwartz formula and by CKD-EPI (mL/min/1,73m2). b Schwartz formula overestimated mGFR with bias 16 ± 15 mL/min/1.73, 95%LOA [− 13 to 45], Bland–Altman method. c Difference between eGFR by CKD-EPI and mGFR according to CKD stages. d CKD-EPI overestimated mGFR with bias 37 ± 22 mL/min/1.73, 95%LOA [− 8 to 78], Bland–Altman method. e Difference between eGFR by Schwartz formula and mGFR according to CKD stages. CKD, chronic kidney disease; GFR, glomerular filtration rate; eGFR, estimated GFR; LOA, limit of agreement; mGFR, measured GFR

Investigation of tubular function


Median serum potassium level was 3.8 mmol/L (2.8 to 4.7 mmol/L). Serum potassium was significantly lower in mut patients (3.3 mmol/L, 2.8 to 3.6 mmol/L) than in mut0 (4.1 mmol/L, 3.7 to 4.1 mmol/L, p = 0.05) and cblA patients (3.9 mmol/L, 3.5 to 4.7 mmol/L, p = 0.02) (Additional file 2: Fig. S2). Three out of 13 patients (#04, #05 and #07), all being mut-, had hypokalemia < 3.5 mmol/L. None of these patients had high blood pressure. A mut0 patient (#13) had plasma potassium at 3.7 mmol/L despite potassium replacement therapy (3.6 g/day) and CKD stage 3b (Table 2). Patients #03, #04 and #05 had inadequate urinary potassium level. Urinary potassium and urinary methylmalonate were strongly correlated (R = 0.77, p = 0.004) (Fig. 4a). Conversely, we found a negative correlation between serum potassium and urinary methylmalonate (R = − 0.61, p = 0.03) (Fig. 4b). Taken together, these results suggest a non-reabsorbable anion effects of urinary methylmalonate that increases kaliuresis. There was no correlation between mGFR and serum potassium.

Fig. 4

Hypokalemia was due to a nonreabsorbable anion effect of methylmalonate. a Urinary potassium (mmol/mmol of creatininuria) was positively associated with urinary methylmalonate (µmol/mmol of creatininuria), R = 0.77, p = 0.004. b Serum potassium (mmol/L) was negatively associated with urinary methylmalonate (µmol/mmol of creatininuria), R = − 0.61, p = 0.03

Table 2 Biological results

Acid–base status

The biological results are summarized in Table 3. All patients had normal alkaline with median alkaline reserve 25 mmol/L (22.3 to 30 mmol/L). Only one patient (#03) received sodium bicarbonate replacement therapy (9 g/day).

Table 3 Characteristics of the 4 patients having urinary loss of potassium

Uric acid

None of the patients had past history of stones or gout. None of the patients had hypouricemia suggestive of proximal tubulopathy. As expected, serum uric acid tended to be inversely proportional to mGFR (p = 0.054).

Phosphocalcic metabolism

Even if all patients received 25OH vitamin D replacement therapy, median 25OH vitamin D was 28 ng/ mL (15 to 76 ng/ mL). Seven out of 13 patients (54%) had 25OH vitamin D deficiency below 30 ng/mL. Median 1-25OH vitamin D was 43 pg/mL (23 to 106 pg/mL). Two patients had 1–25 OH vitamin D deficiency below 30 pg/mL, one of them (#08) having both 25OH and 1-25OH deficiency. Median PTH was 47.2 pg/mL (28.9 to 106.6 pg/ mL, normal value 10–50 pg/mL). Six out of 13 patients (46%) had high PTH level above 50 pg/mL. Hyperparathyroidism was secondary to 25OH vitamin D deficiency in 2 patients and was associated with mGFR below 45 mL/min/1.73 m2 in 4 patients. Two out of 13 patients received calcium replacement therapy. Median ionized calcemia was 1.17 mmol/ L (1.13 to 1.24 mmol/L). Two patients (#07 and #08) had a slight decrease of ionized calcemia below 1.15 mmol/ L, related to a 25OH vitamin D deficiency, with adequate calciuria. Median phosphatemia was 1.0 mmol/L (0.79 to 1.4 mmol/L). Two patients (#05 and #06) had hypophosphatemia below 0.85 mmol/L without renal phosphate leakage, as indicated by normal tubular maximum reabsorption capacity of phosphate (TmP-GFR).


Median magnesium in plasma was 0.83 mmol/L (from 0.68 to 0.96 mmol/L). Three out of 13 patients (#06, #07 and #10) had hypomagnesemia below 0.75 mmol/L. Patient #10 had a high urinary fractional excretion of the magnesium (11.3%), suggesting a renal loss of magnesium. Patients #06 and #07 had suitable fractional excretion of the magnesium.

Urinary markers of tubular dysfunction

No patient had glycosuria. Only one patient, Patient #10, had a marked elevation of β2-microglobulinuria (506 μg/mmol), suggesting proximal tubulopathy. Interestingly, he also had the more severe CKD, defined by mGFR of 23.3 mL/min/1.73m2. The other patients did not display any low molecular weight proteinuria.

To conclude, no patient had complete tubular proximal syndrome. Only one patient (#10) had biological signs suggestive of incomplete proximal tubulopathy with both elevation of β2-microglobulinuria and renal loss of magnesium. Four out of 13 patients had isolated potassium loss related to a non-reabsorbable anion effect.

Glomerular dysfunction markers

No patient had microscopic hematuria or proteinuria above 500 mg/g. Median albumin to creatinine ratio was low 0.8 mg/mmol (0 to 15.4 mg/mmol). Three out of 13 patients (#01, #05 and #08) display albuminuria above 3 mg/mmol.


CKD is a common complication of MMA and worsens long-term prognosis. We precisely studied the renal function of 13 adolescent and adult MMA patients who had not received a liver and/or kidney graft. Our study confirms the high prevalence of CKD in MMA patients: median mGFR was 56.5 mL/min/1.73 m2, 77% of patients had a mGFR below 90 mL/min/1.73 m2, more than half (54%) had at least moderate renal impairment (mGFR below 60 mL/min/1.73 m2), and one had severe renal impairment (mGFR below 15 mL/min/1.73 m2) [5, 9, 14]. Surprisingly, mGFR and vitamin B12-responsiveness were not correlated, even if vitamin B12-responsive patients are considered less severe. Similarly, we did not find any correlation between biochemical phenotype and mGFR. This result contrasts with the expectation that renal function would be poorer in mut0 patients but is likely due to biased sampling of mut0 patients in our study. Indeed, 6 out of 9 MMA patients over 13-years of age followed in our hospital were not included in the present study because they previously received a liver and/or kidney graft (Fig. 1). Furthermore, 6 out of 7 patients that received kidney and/or liver graft before this study were mut0, highlighting the high prevalence of ESRD in mut0 patients. Two out of 3 mut0 patients included in the present study received combined liver and kidney transplantation in the year following the study; the discussion is ongoing for the third patient. Interestingly, protein intake showed a strong positive correlation with eGFR. As protein intake is finely adjusted by dietary management according to metabolic balance, this result suggests a major role of the renal parenchyma in the metabolic balance of MMA. Brassier et al. [12] previously reported metabolic improvement in 4 mut0 patients who received a renal graft alone (without liver graft), which reinforces this hypothesis. After renal transplantation, the number of decompensations per patient per year decreased and the protein intake significantly increased [12]. Whereas liver transplantation, with or without kidney transplantation according to GFR, remains the gold standard to improve the quality of life, the neuropsychological development and the metabolic balance when facing chronic metabolic decompensation, an isolated kidney transplantation could also be individually discussed [30].

It has been suggested that CKD in MMA is the consequence of a tubular dysfunction. No case of glomerulopathy has been reported in the literature and our study supports this data. When performed, renal biopsy showed severe interstitial fibrosis and tubular atrophy [5, 21, 24, 31], with ultrastructural (enlarged mitochondria in proximal tubules) and functional (loss of cytochrome C, decrease in NADPH activity) alterations. These histological findings are consistent with experimental studies suggesting that CKD could be the consequence of mitochondrial dysfunction in proximal tubule [15, 21, 22].

The hypothesis of a chronic tubulopathy is supported by experimental studies [15, 21, 22]. In a murine model of MMA renal disease, mice developed chronic tubulointerstitial nephritis and a decreased GFR associated with megamitochondria formation in the proximal tubules [21, 32, 33]. Targeting mitochondrial dysfunction by administration of coenzyme Q10 and vitamin E, the authors demonstrated that antioxidants attenuate the renal disease induced by high protein diet in a murine model of MMA [21]. In an in vitro model of tubular epithelial cells isolated from urines of MMA patients, Ruppert et al. showed not only a disturbance of energy metabolism in glycolysis, mitochondrial respiratory chain and Krebs cycle but also increased reactive oxygen species formation [22]. Recently, a study demonstrated that metabolic and mitochondrial alterations are exacerbated by anomalies in PINK1/Parking-mitophagy, providing new therapeutic perspectives for MMA [23]. However, few clinical observations support the hypothesis that CKD could be due to a tubulopathy associated with mitochondrial dysfunction [24, 25]. In our study, we precisely characterized tubular functions of MMA patients. No patient had complete tubular proximal syndrome. Only one patient had biological signs suggestive of incomplete proximal tubulopathy with both elevation of β2-microglobulinuria and renal loss of magnesium, but it was associated with severe renal failure. Four out of 13 patients had isolated potassium loss, probably due to a non-reabsorbable anion effect of urinary methylmalonate. Methylmalonate acts as nonreabsorbable anions, enhancing potassium excretion by increasing transtubular potential difference. Such non-reabsorbable anion effect has long been well described with penicillins, also acting as non-reabsorbable anion [34, 35]. Indeed, we found a positive correlation between urinary potassium and urinary methylmalonate as well as a negative correlation between serum potassium and urinary methylmalonate. In clinical practice, patients may experience aggravation of renal function during acute metabolic decompensations, which could partially be explained by toxicity of MMA on renal cells [21, 22, 36]. Moreover, the renal evolution in MMA is completely different from that observed in classical causes of hereditary tubulopathies such as cystinosis or Lowe syndrome. In cystinosis patients, the most common cause of hereditary tubulopathy in pediatrics, severe Fanconi syndrome precedes CKD and ESRD [37]. Lithiasis and nephrocalcinosis are classical features of Lowe syndrome but were not observed in our cohort of MMA patients [38]. Gitelman syndrome, the most common cause of hereditary distal tubular diseases, is also different, associated with profound hypokalemia but normal renal function [39]. Taking together, without excluding involvement of mitochondrial dysfunction in the proximal tubule, these observations suggest a preponderant interstitial origin of CKD in MMA. A better understanding of the mechanisms responsible for CKD in MMA is mandatory to improve the care of these patients.

Furthermore, as expected, eGFR significantly overestimates renal function in MMA patients with low protein diet and reduced muscle mass: + 16 ± 15 mL/min/1.73 m2 with Schwartz formula and + 37 ± 22 mL/min/1.73 m2 with CKD-EPI [40]. Indeed, both formulas are partly based on evaluation of skeletal muscle mass, which is dramatically decreased in MMA patients. Respectively 25% and 90% of MMA patients were misclassified when the Schwartz formula and CKD-EPI formulas were used to categorize subjects according to the KDIGO CKD classification. Therefore, mGFR is essential and should be systematically performed when therapeutic decisions such as dialysis or transplantation are discussed. Schwartz formula was significantly better than CKD-EPI to estimate GFR and had to be preferred if mGFR cannot be performed.

To conclude, CKD is a common complication of the MMA, which worsens long-term prognosis. Mild evidence of proximal tubular dysfunction was found in only one out of 13 patients, suggesting the existence of other mechanisms responsible for CKD during MMA. A better understanding of the mechanisms responsible for CKD in MMA is mandatory to improve the care of these patients.

Availability of data and materials

The data that support the findings of this study are available from the corresponding author upon reasonable request.



Congenital abnormalities of the kidney and the urinary tract


Chronic kidney disease


Estimated glomerular filtration rate


End-stage renal disease


Glomerular filtration rate


Kidney Disease Outcomes Quality Initiative


Methylmalonyl-CoA mutase


Measured glomerular filtration rate


Methylmalonic acidemia


  1. 1.

    Fowler B, Leonard JV, Baumgartner MR. Causes of and diagnostic approach to methylmalonic acidurias. J Inherit Metab Dis. 2008;31(3):350–60.

    CAS  Article  Google Scholar 

  2. 2.

    Jansen R, Kalousek F, Fenton WA, Rosenberg LE, Ledley FD. Cloning of full-length methylmalonyl-CoA mutase from a cDNA library using the polymerase chain reaction. Genomics. 1989;4(2):198–205.

    CAS  Article  Google Scholar 

  3. 3.

    Willard HF, Rosenberg LE. Inherited methylmalonyl CoA mutase apoenzyme deficiency in human fibroblasts: evidence for allelic heterogeneity, genetic compounds, and codominant expression. J Clin Invest. 1980;65(3):690–8.

    CAS  Article  Google Scholar 

  4. 4.

    Baumgartner MR, Hörster F, Dionisi-Vici C, Haliloglu G, Karall D, Chapman KA, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis. 2014;9:130.

    Article  Google Scholar 

  5. 5.

    Cosson MA, Benoist JF, Touati G, Déchaux M, Royer N, Grandin L, et al. Long-term outcome in methylmalonic aciduria: a series of 30 French patients. Mol Genet Metab. 2009;97(3):172–8.

    CAS  Article  Google Scholar 

  6. 6.

    Martín-Hernández E, Lee PJ, Micciche A, Grunewald S, Lachmann RH. Long-term needs of adult patients with organic acidaemias: outcome and prognostic factors. J Inherit Metab Dis. 2009;32(4):523–33.

    Article  Google Scholar 

  7. 7.

    Hörster F, Garbade SF, Zwickler T, Aydin HI, Bodamer OA, Burlina AB, et al. Prediction of outcome in isolated methylmalonic acidurias: combined use of clinical and biochemical parameters. J Inherit Metab Dis. 2009;32(5):630.

    Article  Google Scholar 

  8. 8.

    Nizon M, Ottolenghi C, Valayannopoulos V, Arnoux J-B, Barbier V, Habarou F, et al. Long-term neurological outcome of a cohort of 80 patients with classical organic acidurias. Orphanet J Rare Dis. 2013;8:148.

    Article  Google Scholar 

  9. 9.

    Hörster F, Baumgartner MR, Viardot C, Suormala T, Burgard P, Fowler B, et al. Long-term outcome in methylmalonic acidurias is influenced by the underlying defect (mut0, mut-, cblA, cblB). Pediatr Res. 2007;62(2):225–30.

    Article  Google Scholar 

  10. 10.

    O’Shea CJ, Sloan JL, Wiggs EA, Pao M, Gropman A, Baker EH, et al. Neurocognitive phenotype of isolated methylmalonic acidemia. Pediatrics. 2012;129(6):e1541-1551.

    Article  Google Scholar 

  11. 11.

    Alkhunaizi AM, Al-Sannaa N. Renal involvement in methylmalonic aciduria. Kidney Int Rep. 2017;2(5):956–60.

    Article  Google Scholar 

  12. 12.

    Brassier A, Boyer O, Valayannopoulos V, Ottolenghi C, Krug P, Cosson MA, et al. Renal transplantation in 4 patients with methylmalonic aciduria: a cell therapy for metabolic disease. Mol Genet Metab. 2013;110(1–2):106–10.

    CAS  Article  Google Scholar 

  13. 13.

    de Baulny HO, Benoist JF, Rigal O, Touati G, Rabier D, Saudubray JM. Methylmalonic and propionic acidaemias: management and outcome. J Inherit Metab Dis. 2005;28(3):415–23.

    CAS  Article  Google Scholar 

  14. 14.

    Kruszka PS, Manoli I, Sloan JL, Kopp JB, Venditti CP. Renal growth in isolated methylmalonic acidemia. Genet Med Off J Am Coll Med Genet. 2013;15(12):990–6.

    CAS  Google Scholar 

  15. 15.

    Morath MA, Hörster F, Sauer SW. Renal dysfunction in methylmalonic acidurias: review for the pediatric nephrologist. Pediatr Nephrol Berl Ger. 2013;28(2):227–35.

    Article  Google Scholar 

  16. 16.

    Walter JH, Michalski A, Wilson WM, Leonard JV, Barratt TM, Dillon MJ. Chronic renal failure in methylmalonic acidaemia. Eur J Pediatr. 1989;148(4):344–8.

    CAS  Article  Google Scholar 

  17. 17.

    Pinar-Sueiro S, Martínez-Fernández R, Lage-Medina S, Aldamiz-Echevarria L, Vecino E. Optic neuropathy in methylmalonic acidemia: the role of neuroprotection. J Inherit Metab Dis. 2010;33(Suppl 3):S199-203.

    Article  Google Scholar 

  18. 18.

    Traber G, Baumgartner MR, Schwarz U, Pangalu A, Donath MY, Landau K. Subacute bilateral visual loss in methylmalonic acidemia. J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc. 2011;31(4):344–6.

    Article  Google Scholar 

  19. 19.

    Marquard J, El Scheich T, Klee D, Schmitt M, Meissner T, Mayatepek E, et al. Chronic pancreatitis in branched-chain organic acidurias—a case of methylmalonic aciduria and an overview of the literature. Eur J Pediatr. 2011;170(2):241–5.

    Article  Google Scholar 

  20. 20.

    Morath MA, Okun JG, Müller IB, Sauer SW, Hörster F, Hoffmann GF, et al. Neurodegeneration and chronic renal failure in methylmalonic aciduria–a pathophysiological approach. J Inherit Metab Dis. 2008;31(1):35–43.

    CAS  Article  Google Scholar 

  21. 21.

    Manoli I, Sysol JR, Li L, Houillier P, Garone C, Wang C, et al. Targeting proximal tubule mitochondrial dysfunction attenuates the renal disease of methylmalonic acidemia. Proc Natl Acad Sci USA. 2013;110(33):13552–7.

    CAS  Article  Google Scholar 

  22. 22.

    Ruppert T, Schumann A, Gröne HJ, Okun JG, Kölker S, Morath MA, et al. Molecular and biochemical alterations in tubular epithelial cells of patients with isolated methylmalonic aciduria. Hum Mol Genet. 2015;24(24):7049–59.

    CAS  PubMed  Google Scholar 

  23. 23.

    Luciani A, Schumann A, Berquez M, Chen Z, Nieri D, Failli M, et al. Impaired mitophagy links mitochondrial disease to epithelial stress in methylmalonyl-CoA mutase deficiency. Nat Commun. 2020;11(1):970.

    CAS  Article  Google Scholar 

  24. 24.

    Ohura T, Kikuchi M, Abukawa D, Hanamizu H, Aikawa J, Narisawa K, et al. Type 4 renal tubular acidosis (subtype 2) in a patient with methylmalonic acidaemia. Eur J Pediatr. 1990;150(2):115–8.

    CAS  Article  Google Scholar 

  25. 25.

    Wolff JA, Strom C, Griswold W, Sweetman F, Kulovich S, Prodanos C, et al. Proximal renal tubular acidosis in methylmalonic acidemia. J Neurogenet. 1985;2(1):31–9.

    CAS  Article  Google Scholar 

  26. 26.

    The Kidney Disease. Improving Global Outcomes (KDIGO) 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1–150.

    Article  Google Scholar 

  27. 27.

    Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol JASN. 2009;20(3):629–37.

    Article  Google Scholar 

  28. 28.

    Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.

    Article  Google Scholar 

  29. 29.

    Dinkel E, Ertel M, Dittrich M, Peters H, Berres M, Schulte-Wissermann H. Kidney size in childhood Sonographical growth charts for kidney length and volume. Pediatr Radiol. 1985;15(1):38–43.

    CAS  Article  Google Scholar 

  30. 30.

    Brassier A, Krug P, Lacaille F, Pontoizeau C, Krid S, Sissaoui S, et al. Long-term outcome of methylmalonic aciduria after kidney, liver or combined liver-kidney transplantation: the French experience. J Inherit Metab Dis. 2020;43(2):234–43.

  31. 31.

    Zsengellér ZK, Aljinovic N, Teot LA, Korson M, Rodig N, Sloan JL, et al. Methylmalonic acidemia: a megamitochondrial disorder affecting the kidney. Pediatr Nephrol Berl Ger. 2014;29(11):2139–46.

    Article  Google Scholar 

  32. 32.

    Peters H, Nefedov M, Sarsero J, Pitt J, Fowler KJ, Gazeas S, et al. A knock-out mouse model for methylmalonic aciduria resulting in neonatal lethality. J Biol Chem. 2003;278(52):52909–13.

    CAS  Article  Google Scholar 

  33. 33.

    Chandler RJ, Zerfas PM, Shanske S, Sloan J, Hoffmann V, DiMauro S, et al. Mitochondrial dysfunction in mut methylmalonic acidemia. FASEB J Off Publ Fed Am Soc Exp Biol. 2009;23(4):1252–61.

    CAS  Google Scholar 

  34. 34.

    Brunner FP, Frick PG. Hypokalaemia, metabolic alkalosis, and hypernatraemia due to “massive” sodium penicillin therapy. Br Med J. 1968;4(5630):550–2.

    CAS  Article  Google Scholar 

  35. 35.

    van der Heijden CDCC, Duizer ML, Fleuren HWHA, Veldman BA, Sprong T, Dofferhoff ATSM, et al. Intravenous flucloxacillin treatment is associated with a high incidence of hypokalaemia. Br J Clin Pharmacol. 2019;85(12):2886–90.

    Article  Google Scholar 

  36. 36.

    Jiang Y-Z, Shi Y, Shi Y, Gan L-X, Kong Y-Y, Sun L-Y, et al. Factors influencing in-hospital death for pediatric patients with isolated methylmalonic acidemia: a nationwide inpatient database analysis. Orphanet J Rare Dis. 2020;15(1):154.

    Article  Google Scholar 

  37. 37.

    Elmonem MA, Veys KR, Soliman NA, van Dyck M, van den Heuvel LP, Levtchenko E. Cystinosis: a review. Orphanet J Rare Dis. 2016;11:47.

    Article  Google Scholar 

  38. 38.

    Bockenhauer D, Bokenkamp A, van’t Hoff W, Levtchenko E, Kist-van Holthe JE, Tasic V, et al. Renal phenotype in Lowe Syndrome: a selective proximal tubular dysfunction. Clin J Am Soc Nephrol CJASN. 2008;3(5):1430–6.

    Article  Google Scholar 

  39. 39.

    Blanchard A, Bockenhauer D, Bolignano D, Calò LA, Cosyns E, Devuyst O, et al. Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2017;91(1):24–33.

    Article  Google Scholar 

  40. 40.

    Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol JASN. 2005;16(3):763–73.

    Article  Google Scholar 

Download references


Not applicable.


This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information




JBA, FB, PD, AS: conception and design; MD, FB, FB, JFB, CP, CO, OB, AS: analysis and interpretation of data; MD, FB, AS: drafting the article; JBA, AB, JFB, CP, CO, OB, AS: revising the article; MD, JBA, FB, AB, JFB, CP, CO, PK, OB, PD, AS: providing intellectual content of critical importance. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Myriam Dao.

Ethics declarations

Ethics approval and consent to participate

This study was performed in accordance with the ethical standards of the Helsinki Declaration.

Consent for publication

All patients provided authorization for the use of their information for research purposes.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Fig. S1

. Methylmalonic acidemia is caused by a defect in the mitochondrial methylmalonyl-CoA mutase (MCM). MCM isomerises L-methylmalonyl-CoA into succinyl-CoA which enters the Krebs cycle. Its cofactor is adenosylcobalamin. The MUT, MMAA and MMAB genes respectively encode for MCM, CblA and CblB. MCM deficiencies are due to mutations in the MUT gene or to mutations in MMAA or MMAB. MCM deficiency results in accumulation of toxic metabolites such as 3-hydroxypropionic acid, methylcitric acid and most markedly, methylmalonic acid.

Additional file 2: Fig. S2

. Serum potassium was lower in patients with mut- phenotype. Medians ± interquartile ranges.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dao, M., Arnoux, JB., Bienaimé, F. et al. Long-term renal outcome in methylmalonic acidemia in adolescents and adults. Orphanet J Rare Dis 16, 220 (2021).

Download citation


  • Methylmalonic acidemia
  • Chronic kidney disease
  • Measured glomerular filtration rate
  • Estimated glomerular filtration rate
  • Tubulopathy